$54.61
1.41% yesterday
Nasdaq, Jun 13, 10:00 pm CET
ISIN
NL0011606264
Symbol
MRUS
Sector
Industry

Merus N.V. Stock price

$54.61
+13.69 33.46% 1M
+11.78 27.50% 6M
+12.56 29.87% YTD
-3.04 5.27% 1Y
+39.46 260.46% 5Y
+44.57 443.92% 10Y
+44.57 443.92% 20Y
Nasdaq, Closing price Fri, Jun 13 2025
-0.78 1.41%
ISIN
NL0011606264
Symbol
MRUS
Sector
Industry

Key metrics

Market capitalization $4.13b
Enterprise Value $3.67b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 67.00
P/S ratio (TTM) P/S ratio 75.37
P/B ratio (TTM) P/B ratio 6.43
Revenue growth (TTM) Revenue growth 42.75%
Revenue (TTM) Revenue $54.73m
EBIT (operating result TTM) EBIT $-301.00m
Free Cash Flow (TTM) Free Cash Flow $-239.85m
Cash position $458.33m
EPS (TTM) EPS $-4.01
P/E forward negative
P/S forward 75.04
EV/Sales forward 66.70
Short interest 6.75%
Show more

Is Merus N.V. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.

Merus N.V. Stock Analysis

Unlock Scores for Free

Analyst Opinions

18 Analysts have issued a Merus N.V. forecast:

18x Buy
100%

Analyst Opinions

18 Analysts have issued a Merus N.V. forecast:

Buy
100%

Financial data from Merus N.V.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
55 55
43% 43%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 89 89
47% 47%
162%
- Research and Development Expense 267 267
85% 85%
488%
-299 -299
82% 82%
-545%
- Depreciation and Amortization 2.45 2.45
5% 5%
4%
EBIT (Operating Income) EBIT -301 -301
81% 81%
-550%
Net Profit -277 -277
85% 85%
-507%

In millions USD.

Don't miss a Thing! We will send you all news about Merus N.V. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Merus N.V. Stock News

Positive
Seeking Alpha
3 days ago
MRUS initially surged on superior interim trial data while BCAX tanked, but BCAX has since rebounded post-ASCO as investors reconsider the data and target market. BCAX targets the tougher HPV-negative head and neck cancer segment, representing 80% of cases, and boasts a higher complete response rate than MRUS. Despite analyst preference for MRUS, BCAX's durability argument and deep response rat...
Neutral
GlobeNewsWire
10 days ago
UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced the pricing of an underwritten public offering of 5,263,158 common shares, at a p...
Neutral
GlobeNewsWire
10 days ago
UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Merus N.V.
More Merus N.V. News

Company Profile

Merus NV is a clinical-stage immune-oncology company, which engages in the discovery and development of bi-specific antibody therapeutics. Its pipeline includes Biclonics for solid and hematological tumors. The company was founded by Ton Logtenberg on June 16, 2003 and is headquartered in Utrecht, Netherlands.

Head office Netherlands
CEO Bill Lundberg
Employees 291
Founded 2003
Website merus.nl

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today